The Synthesis of antiCD3-F(ab’)2 and Fab, and the Biodistribution of an antiCD3-F(ab’)2 Radiotracer in C57BL/6J and BALB/c mice by Soliman, Luke
 
 
 
 
 
 
 
 
 
 
 
The Synthesis of antiCD3-F(ab’)2 and Fab, and the Biodistribution of an antiCD3-F(ab’)2 
Radiotracer in C57BL/6J and BALB/c mice 
 
 
 
 
 
 
 
By 
Luke B. Soliman 
 
 
 
 
 
 
Senior Honors Thesis 
Department of Chemistry 
University of North Carolina at Chapel Hill 
 
November 10, 2017 
 
 
 
 
 
 
 
 
 
 
 
 
Advisor: Matthew C. Parrott, PhD 
 2 
Abstract 
Background: The activation of tumor-infiltrating lymphocytes (TILs) has become a 
prominent immunotherapy technique for the treatment of various cancers. The binding of 
the antiCD3 immunoglobulin (IgG) to the CD3 T-cell receptor (TCR) produces the 
cytotoxic T-cell, thereby eliciting an immune response against biological malignancies. 
In addition to the therapeutic action that these T-cells induce, imaging of these cells 
serves as a foundation to monitor immunotherapy treatment efficacy. Antigen binding 
fragments, derived from full-sized therapeutic monoclonal antibodies (mAbs), have been 
shown to bind identically to their parent mAbs while also exhibiting more rapid clearance 
from the bloodstream. We developed novel protocols for the production of antiCD3 
antigen binding fragments, characterized the fragments, and preliminarily evaluated their 
capabilities to rapidly and non-invasively analyze the efficacy of TIL therapy. 
Methods: A monoclonal antiCD3 antibody (mAb) was enzymatically digested into Fab 
and F(ab’)2 fragments by ficin and pepsin respectively. The antiCD3-F(ab’)2 fragment 
was isolated by size-exclusion high-performance liquid chromatography (SE-HPLC), and 
characterized by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), dynamic light scattering (DLS), and SE-HPLC. The fragment was then 
conjugated with the metal chelating agent p-SCN-Bn-NOTA (NOTA), radiolabeled with 
copper-64 (Cu-64 or 64Cu), and injected into immunocompetent (C57BL/6J) and 
immunocompromised (BALB/c) mice. 64Cu labeled antiCD3-F(ab’)2 uptake was 
evaluated ex vivo by measurement of radioactivity in target tissues at 6 h and 24 h post-
tail vein injection. 
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Result: Protocols for the digestion of antiCD3 to crude Fab and F(ab’)2 were developed 
and optimized. SE-HPLC purification was successfully performed to isolate the antiCD3-
F(ab’)2 fragment. The percent injected dose per gram of tissue (%ID/g) of 64Cu-NOTA-
antiCD3-F(ab’)2 between black and nude mice was statistically significant for the spleen 
at 6 h, and for the kidney, spleen, cervical lymph node (CLN), and axillary lymph node 
(ALN) at 24 h. 
Conclusion: Novel protocols for the fragmentation and purification of an antiCD3 mAb 
to Fab and F(ab’)2 were developed. The conjugated, radiolabeled antiCD3-F(ab’)2 
fragment showed rapid clearance via the kidney, significant uptake in several lymphoid 
organs, and further potential for development as an imaging agent for cancer 
immunotherapy efficacy. 
Introduction 
Substantial evidence has emerged that many tumors express antigens that can be 
recognized by the immune system, making immunotherapy a rational approach for the 
treatment of cancer.1 Of the many cancer immunotherapy techniques under review, one 
emerging method is the recruitment of cytotoxic T-cells which are signaled by the 
binding of antibodies to T-cell receptors (TCRs). Additionally, treatment efficacy can be 
evaluated by monitoring the immune response during therapy.2,3 The CD3 antigen, which 
is present in TCRs at all stages of T-cell development, makes it a useful target for the 
signaling and mobilization of T-cells. Thus, the CD3 antigen is also a natural point of 
interest for the early evaluation of the efficacy of immunotherapy treatments.4 
 The significance of this project is two-pronged. Rather than directly target a 
cancer cell antigen to signal cell death, it indirectly treats cancer by binding an antigen 
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located within an immune cell to thereby stimulate a therapeutic immune response. In 
addition, this project also makes use of antibody fragments, rather than full 
immunoglobulin proteins. The latter, nuanced aim is significant for several reasons. First, 
the labeling of a suitable radioisotope to an undigested antibody without inflicting 
damage to its binding behavior can be demanding.2 Damaged antibodies would fail to 
serve as effective tumor imaging agents, and would also reduce the potency of 
immunotherapy treatment. Second, full antibodies exhibit poorer tissue penetration than 
antibody fragments.2 Imaging agents that are able to better penetrate tissue and therefore 
saturate tumor binding sites will optimize the resolution of PET/CT tumor images. Third, 
whole antibodies ( ~150 kDa) persist in bodily circulation for greater periods than do 
their fragments (~50 – 110 kDa).2 One challenge of non-invasive tumor imaging is 
reducing the residual radioactivity that is exposed to the patient – this obstacle is 
alleviated by the use of antibody fragments which circulate for shorter periods of time. 
This project, founded in the two aforementioned nuances, takes advantage of 
techniques in enzymatic proteolysis and antibody binding behavior to evaluate the 
biodistribution of antiCD3-F(ab’)2 in vivo – and serves as a basis for subsequent study of 
rapid and non-invasive evaluation of tumor size, location, and the efficacy of cancer 
immunotherapy treatments.  
We hypothesized that pepsin and ficin would enzymatically proteolyze antiCD3-
IgG to F(ab’)2 and Fab respectively, and that an antiCD3-F(ab’)2 fragment radiolabeled 
with 64Cu would accumulate T-cells with statistical significance between 
immunocompetent and immunocompromised mice. 
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Materials and Methods 
Reagents and instruments 
AntiCD3 (BE0002) was purchased from BioXCell (West Lebanon, NH).The bifunctional 
chelator, 2-S-(4-Isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-
SCN-Bn-NOTA) was purchased from Macrocyclics (Dallas, TX, USA). Copper-64 in 1 
M oxalic acid was purchased from Washington University (MO, USA). All other 
reagents were purchased from Fisher Scientific with the highest purity available. Protein 
concentration was determined using a Nanodrop 2000/2000c. Radioactivity from non-
biological samples was measured in a CRC-55tW dose calibrator/well counter (Capintec, 
NJ, USA). Radioactivity in biological samples was measured in an automatic γ-counter 
(2470, Wizard2, Perkin Elmer, Walthem, MA). Size-exclusion high- performance liquid 
chromatography (SE-HPLC) was performed at room temperature on an Agilent 1200 
series chromatographic system equipped with an online flow γ-ray detector (Lablogic). 
Samples were injected onto Agilent Bio SEC-5 size exclusion column (5 µm, 300 Å; 7.8 
x 300 mm) and Agilent Bio SEC-5 size exclusion column (5 µm, 100 Å; 7.8 x 300 mm) 
connected in series using EDTA 0.01 M in PBS as the isocratic mobile phase. The flow 
rate was maintained at 1 mL/min and the elution was monitored by UV 
spectrophotometer at 254 and 280 nm. Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) was carried out in an XCell SureLockTM Mini-Cell 
electrophoresis system.  
Dynamic Light Scattering Analysis of antiCD3-IgG, F(ab’)2, and Fc 
Dynamic light scattering was performed in a Zetasizer Nano ZS Particle Analyzer 
(Malvern, Inc.) on 0.1 mg/mL of sample in a disposable microcuvette at 25o C. 
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Automatic measurement duration and 173° backscatter protein analysis model were used 
for measurements, which were taken in triplicate. 
Fragmentation of antiCD3-IgG to F(ab’)2 
To a Vivaspin 2 (30 kDa molecular weight cut off (MWCO)) filter, 1 mg (3.1 mg/mL, 
322.5 µL) of antiCD3 IgG in stock solution was added. The solution was concentrated by 
ultracentrifugation for 10 min at 5000 RCF at 4 oC. The antibody was then buffer 
exchanged to F(ab’)2 digestion buffer (ThermoFisher) by adding 1 mL of buffer to the 
filter, centrifuging for 10 min, and recovering the retentate. To a 2 mL spin column, 0.5 
mL immobilized pepsin was added and centrifuged for 1 min at 5000 RCF at 4 oC. The 
filtrate was recovered, and 500 µL of F(ab’)2 digestion buffer was added to the column. 
The pepsin was then washed with digestion buffer by ultracentrifugation for 1 min at 
5000 RCF at 4 oC. Solid pepsin was then transferred into a 1.5 mL conical reaction vial. 
The concentrated solution of antiCD3 IgG was added to the reaction vial, and F(ab’)2 
digestion buffer was added to yield a total reaction volume of 500 µL. The reaction 
mixture was then incubated at 37 oC and mixed at 400 RPM and monitored hourly by SE-
HPLC. After 3 h, the reaction mixture was transferred to a spin column and centrifuged at 
5000 RCF for 1 min at 4 oC to remove immobilized enzyme. The filtrate was collected, 
transferred to a new vial, and the resin was washed twice with 500 µL 0.1 M PBS. Both 
washing fractions were combined  with the original filtrate in a Vivaspin 2 (30 kDa 
MWCO), and concentrated by ultracentrifugation for 10 min at 5000 RCF at 4 oC. The 
concentrated solution was then buffer exchanged by adding 1.0 mL of 0.1 M PBS to the 
filter, centrifuging 10 min at 5000 RCF at 4 oC, and repeating. The retentate was then 
retrieved and stored at 4 oC. 
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Fragmentation of antiCD3-IgG to Fab 
To 10 mL of Fab digestion buffer (ThermoFisher), 43.9 mg L-cysteine•HCl was 
dissolved to yield 25 mM cysteine solution. An identical fragmentation protocol to the 
one above was followed, instead substituting 25 mM cysteine buffer rather than F(ab’)2 
buffer, using 1 mL of immobilized ficin rather than 500 µL of immobilized pepsin, and 
allowing the reaction to proceed for 80 min rather than 3 h. 
 
SE-HPLC purification of antiCD3 fragments 
Crude F(ab’)2 and Fab were isolated by SE-HPLC purification. Samples of 150 µg were 
injected onto the column with an isocratic mobile phase of 0.01 M PBS flowing at 1.0 
mL/min. Pure F(ab’)2 was collected from 13:55 (mm:ss) to 14:25. Pure Fab was retrieved 
from 15:01 to 15:31. AntiCD3-Fc was isolated by collecting fractions from 16:07 to 
16:25. 
Biodistribution of  64Cu-NOTA-antiCD3-F(ab’)2 in immunocompetent and 
immunocompromised mice 
Two groups of C57BL/6J and BALB/c mice were intraveneously injected with 30.1 ± 
1.30 uCi of 64Cu-NOTA-antiCD3-F(ab’)2. At 6 h and 24 h post-tail vein injection, 6 mice 
from each group were sacrificed, and blood, liver, spleen, kidney, cervical lymph node 
(CLN), axillary lymph node (ALN), inguinal lymph node (ILN), bone, and the carcass 
were collected. The tissues were weighed and measured ex vivo for radioactivity. The 
percent of injected dose per gram of tissue (%ID/g) was calculated, and the data was then 
subject to statistical analysis. 
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Statistical Analysis 
Differences between groups were tested for significance using a T-test and Mann-
Whitney Test. Outliers were determined by Grubb’s test and removed from future 
calculation. P values were calculated using a two-tailed test, and values ≤ 0.05 were 
considered significant. Data are reported as mean ± standard deviation. 
Results 
Fragmentation of antiCD3 to F(ab’)2 and Fab 
Although the reaction of antiCD3-IgG with immobilized pepsin is optimized at 3 h, only 
0.63% of the full immunoglobulin remains undigested after the first hour. Table 1 
indicates the percent conversions between undigested antibody and the fragmented 
products over time, as calculated by the area under each peak in the respective SE-HPLC 
chromatogram for that timepoint (λ = 280 nm). After filtration in a 30 kDa MWCO filter, 
the reaction of antiCD3-IgG with immobilized pepsin, forming F(ab’)2, had a crude yield 
of 47.46%. SE-HPLC characterization of Crude antiCD3-F(ab’)2  can be found in Figure 
1. For comparison, Figure 2 depicts the chromatogram of SE-HPLC analysis of antiCD3-
IgG. Of the crude product, 87.97% was antiCD3-F(ab’)2. Therefore, for each 1.0 mg of 
antiCD3-IgG reacted, 0.4175 mg of unisolated F(ab’)2 is produced.   
Table 1. Percent conversions from antiCD3-IgG to F(ab’)2 and Fc fragments during 
enzymatic proteolysis with pepsin 
 
Time (h) IgG (%) F(ab’)2 (%) Fc (%) 
0 100 0 0 
1 h 0.63 9.55 89.82 
2 h 0.59 8.65 90.76 
Crude (post-filtration) 1.19 87.97 10.84 
Purified (by HPLC) 0.57 99.43 0 
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Table 2, shown below, indicates the percent conversions of reactants to products 
for the digestion of antiCD3-IgG with ficin, as calculated by the area under each peak in 
the respective SE-HPLC chromatogram for that timepoint (λ = 280 nm). Within the first 
40 min of the reaction, 98.87% of the IgG was digested into its constituent fragments. By 
the end of the digestion at 80 min, 0% of the intact antibody remained. After filtration of 
the reaction mixture in a 10 kDa MWCO filter, the average crude yield of the reaction 
was 68.0%. The SE-HPLC analysis of crude antiCD3-Fab is shown in Figure 3. Of the 
total amount of protein in the crude product, 17.72% was unisolated Fab. Therefore, for a 
1:1 reaction of antiCD3-IgG with immobilized ficin slurry, 120 µg of unisolated Fab is 
produced. 
Table 2. Percent conversions of antibody fragments from antiCD3 during fragmentation 
with ficin 
Time (min) IgG (%) Fab (%) Fc (%) 
0 95.89 0.12 3.99 
20 13.27 22.85 63.88 
40 1.13 24.63 74.24 
60 0.02 23.71 76.28 
80 0 20.73 79.27 
Crude (post-filtration) 0 17.72 82.28 
 
SE-HPLC Purification of F(ab’)2 and Fab 
Crude F(ab’)2 was isolated from undigested IgG and Fc with a yield of 3.38% (Table 3). 
For each 1.0 mg of antiCD3-IgG fragmented with pepsin, 16.03 µg of antiCD3-F(ab’)2 
was purified and retrieved. Pure F(ab’)2 was characterized by SE-HPLC, shown in Figure 
4. Crude Fab was isolated from undigested IgG and Fc with a yield of 0.33% (Table 4). 
For each 1.0 mg of antiCD3-IgG fragmented with ficin, 2.27 µg of antiCD3-Fab was 
purified and isolated.  
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Table 3. Yields of total protein and F(ab’)2 during F(ab’)2 fragmentation and SE-HPLC 
purification 
 Percent (%) Mass (µg) 
Total Crude Protein Yield 47.46 474.60 
Unisolated F(ab’)2 within 
Total Crude Protein 
87.97 417.50 
HPLC Purified F(ab’)2 Yield 3.38 16.03 
Overall antiCD3-IgG to Pure 
F(ab’)2 Yield 
1.60 16.03 
 
Table 4. Yields of total protein and Fab during Fab fragmentation and SE-HPLC 
purification 
 Percent (%) Mass (µg) 
Total Crude Protein Yield 68.00 680.00 
Unisolated Fab within Total 
Crude Protein 
17.72 120.50 
HPLC Purified Fab Yield 0.33 2.27 
Overall antiCD3-IgG to Pure 
Fab Yield 
0.227 2.27 
 
Dynamic Light Scattering of antiCD3 IgG, F(ab’)2, and Fc 
Isolated antiCD3-IgG, F(ab’)2, and Fc were evaluated by dynamic light scattering to 
estimate the spherical diameter of each molecule. Table 5 below indicates the measured 
diameters and their respective standard deviations. 
Table 5. antiCD3 immunoglobulin and fragment diameters, as characterized by dynamic 
light scattering 
 Diameter (nm) St. Dev. (nm) 
antiCD3-IgG 10.23 0.526 
antiCD3-F(ab’)2 8.45 0.187 
antiCD3-Fc 7.01 0.363 
 
Figures 5-7 graphically depict the size measurements for each of the proteins. 
 
 
Biodistribution of  64Cu-NOTA-antiCD3-F(ab’)2 in immunocompetent and 
immunocompromised mice 
T-cells, often founds in lymphoid organs, become radiolabeled second-handedly upon the 
binding of  64Cu-NOTA-antiCD3-F(ab’)2 to the CD3 antigen. Therefore, ex vivo 
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measurement of radioactivity in target tissues serves as a rational foundation for the 
determination of antiCD3-F(ab’)2 biodistribution. 
Figure 8 graphically illustrates the percent injected dose per gram of tissue 
(%ID/g) for both immunocompetent and immunocompromised mice at 6 h post tail vein 
injection. AntiCD3-F(ab’)2 exhibited rapid clearing via the kidney for both types of mice, 
averaging 69.16 and 73.23 %ID/g for black and nude mice respectively. The lymphoid 
organs, which serve as storehouses for immune cells, are the only tissues at both 6 h and 
24 h to show a statistically significant difference in uptake of antiCD3-F(ab’)2 between 
black and nude mice. At 6 h, the cervical lymph node (CLN) and axillary lymph node 
(ALN) showed significantly greater uptake in black mice than in nude (p < 0.01). The 
spleen showed even greater significance between black and nude mice in F(ab’)2 uptake 
(p < 0.001). Other ex vivo samples, such as the liver, bone, blood, and carcass failed to 
show significance in fragment uptake between black and nude mice. 
Ex vivo analysis of target tissues at 24 h post tail vein injection (Figure 9) 
revealed significantly higher uptake in the spleen (p < 0.001), CLN (p < 0.001), and ALN 
(p < 0.01) for black mice than in nude mice. Nude mice demonstrated higher antiCD3-
F(ab’)2 uptake in the kidney (p < 0.01) than black mice. Other measured peripheral 
tissues exhibited non-significant differences in fragment uptake between the two types of 
mice. Table 6, below, tabulates the specific values for %ID/g for each tissue, for black 
and nude mice at 6 h and 24 h.  
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Table 6. Average percent injected dose per gram of tissue (%ID/g) at 6 h and 24 h for 
both immunocompetent and immunocompromised mice, with corresponding P value and 
significance level (* p<0.05, ** p<0.01, *** p<0.001, ns = not significant).  
*Note: one data point (inguinal LN from a black mouse at 6 h) was removed as it was a 
significant outlier (p < 0.05) by Grubbs’ test 
 
 
Discussion 
This manuscript is the first to report protocol for the fragmentation and purification of an 
antiCD3 immunoglobulin to F(ab’)2 and Fab, and to describe the uptake of an antiCD3-
F(ab’)2 radiotracer in vivo in immunocompetent and immunocompromised mice. These 
methods and results set forth a foundation for the future evaluation of antiCD3 fragments 
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as PET/CT imaging agents for the evaluation of immunotherapy treatment efficacy, as 
well as potential use in immunotherapy. 
 One approach of cancer immunotherapy hinges on the ability of the treatment to 
successfully produce cytotoxic T-cells and to traffic tumor infiltrating lymphocytes 
(TILs) in the fight against bodily malignancies. The lymphoid organs, which serve as 
storehouses for immune cells, are integral players in the mobilization of T-cells. The 
biodistribution data discussed in this report demonstrate statistically significant 
differential uptake of 64Cu-NOTA-antiCD3-F(ab’)2. between black and nude mice in the 
spleen, CLN, and ALN at 6 h. Nude mice showed a significantly higher uptake of 
radioactivity in the kidney than did black mice at 24 h. This could possibly indicate that 
immunocompetent mice, which bear T-cells, uptake and retain antiCD3-F(ab’)2 in other 
tissues. This conclusion is supported by the data, which indicates that at 24 h, lymphoid 
organs such as the spleen, CLN, and ALN showed statistically significant higher uptakes 
of radioactivity in black mice than in nude mice. AntiCD3-F(ab’)2 therefore shows 
incredible promise in its ability to as a useful imaging marker to monitor lymphocytes 
and analyze TIL recruitment efforts in immunotherapy treatment. 
Conclusions 
An antiCD3 immunoglobulin was successfully fragmented and purified to F(ab’)2 and 
Fab. AntiCD3-IgG, F(ab’)2, and Fc were characterized by dynamic light scattering for 
their diameters. A radiolabeled antiCD3-F(ab’)2 fragment was injected into 
immunocompetent and immunocompromised mice, and the tissue biodistribution was 
evaluated ex vivo. The fragment showed rapid clearance via the kidney and statistically 
significant uptake in lymphoid organ tissues of immunocompetent mice compared to 
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immunocompromised mice. AntiCD3-F(ab’)2  demonstrates incredible future promise as 
a PET/CT imaging agent and analytical tool for  evaluating the efficacy for cancer 
immunotherapy treatment.  
Figure Legend 
 
Figure 1. Crude antiCD3-F(ab’)2, post-30 kDa MWCO filtration. In order of earliest   
elution time to latest: antiCD3-IgG (13:45), F(ab’)2 (14:32), Fc (16:09)  
 
 
Figure 2. Undigested antiCD3-IgG (Tr = 13:45) 
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Figure 3. Crude antiCD3-Fab post-10 kDa MWCO filtration. In order of earliest elution 
time to latest: antiCD3-IgG (13:45), Fab (14:58), Fc (16:09) 
 
 
 
Figure 4. Pure ( > 99%) antiCD3-F(ab’)2 (14:32) 
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Figure 5. Dynamic light scattering analysis of antiCD3-IgG (Diameter = 10.23 nm) 
 
Figure 6. Dynamic light scattering analysis of antiCD3-F(ab’)2 (Diameter = 8.45 nm) 
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Figure 7. Dynamic light scattering analysis of antiCD3-Fc (Diameter = 7.01 nm) 
 
Figure 8. Biodistribution of antiCD3-F(ab’)2 in black and nude mice at 6 h (* p<0.05, ** 
p<0.01, *** p<0.001). 
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Figure 9. Biodistribution of antiCD3-F(ab’)2 in black and nude mice at 24 h. 
 
Supplemental Information 
Supplemental Figures: 
 
Figure S1. Crude NOTA-antiCD3-F(ab’)2 (14:12) and Fc (16:09) 
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Figure S2. Purified NOTA-antiCD3-F(ab’)2 (14:12) 
 
 
Figure S3. 64Cu-NOTA-antiCD3-F(ab’)2 (14:11) 
 
Figure S4. Trace of radioactive counts for 64Cu-NOTA-antiCD3-F(ab’)2 (14:11) 
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Supplemental Materials and Methods: 
One area of consideration for future antiCD3-F(ab’)2 fragmentations lies in the accuracy 
of the amount of pepsin used. While the novel reaction protocol discussed here calls for 
500 µL of immobilized pepsin for each 1.0 mg of antiCD3-IgG, the density of the pepsin 
slurry can vary from 2 mg/mL to 3 mg/mL.5 Although gently stirring the resin does help 
to evenly distribute the enzyme throughout the mixture, there still exists a margin of 
uncertainty for the exact stoichiometric ratio of digestive enzyme to antibody. 
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